Twist Bioscience reported a record-setting QQ3 2024 quarter with revenue of $81.5 million, up 28% year over year, driven by robust demand in SynBio (Express Genes portfolio) and strong NGS performance. Gross margin improved by approximately 900 basis points to 43.3% versus 34.4% a year ago, supported by Express Genes and favorable NGS mix. Management highlighted ongoing product expansion (Multiplexed Gene Fragments up to 500 bp, Express Antibodies for CHO and HEK293) and a growing MRD/NDRD pipeline in NGS, plus BIopharma activity with an impairment in the quarter. Net income was -$85.6 million and adjusted EBITDA was -$22 million, reflecting the company’s continued investment phase and one-time impairment charges in Biopharma. Cash position remained solid at about $289.4 million, with operating cash flow improving sequentially. The company guided for FY2024 revenue of roughly $310–$311 million (up ~27%), with 4Q revenue guidance of $82–$83 million and gross margin around 44%. Importantly, Twist reiterated a multi-quarter path to margin expansion and profitability, forecasting gross margins north of 50% by the end of FY2025 and adjusted EBITDA breakeven in the near term. The results and commentary position Twist as a high-velocity growth company—prioritizing margin improvements, capacity expansion, and portfolio breadth to sustain above-market growth in SynBio and NGS while managing Biopharma impairment and geopolitical headwinds in BioSecure.